292 related articles for article (PubMed ID: 21231957)
1. Renin-angiotensin-aldosterone system blockade and urinary albumin excretion in community-based patients with Type 2 diabetes: the Fremantle Diabetes Study.
Fegan PG; Davis WA; Kamber N; Sivakumar S; Beilby J; Davis TM
Diabet Med; 2011 Jul; 28(7):849-55. PubMed ID: 21231957
[TBL] [Abstract][Full Text] [Related]
2. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
de Zeeuw D
Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.
Bakris GL; Toto RD; McCullough PA
J Hum Hypertens; 2005 Feb; 19(2):139-44. PubMed ID: 15457206
[TBL] [Abstract][Full Text] [Related]
4. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.
Nielsen SE; Persson F; Frandsen E; Sugaya T; Hess G; Zdunek D; Shjoedt KJ; Parving HH; Rossing P
Diabet Med; 2012 Aug; 29(8):e184-90. PubMed ID: 22268920
[TBL] [Abstract][Full Text] [Related]
5. The role of angiotensin receptor blockers in diabetic nephropathy.
Sharma AM; Weir MR
Postgrad Med; 2011 May; 123(3):109-21. PubMed ID: 21566421
[TBL] [Abstract][Full Text] [Related]
6. The impact of renin-angiotensin-aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy.
Hirst JA; Taylor KS; Stevens RJ; Blacklock CL; Roberts NW; Pugh CW; Farmer AJ
Kidney Int; 2012 Apr; 81(7):674-83. PubMed ID: 22189841
[TBL] [Abstract][Full Text] [Related]
7. ACE inhibitors or ARBs for diabetic nephropathy: the unrelenting debate.
Kota SK; Meher LK; Jammula S; Kota SK; Modi KD
Diabetes Metab Syndr; 2012; 6(4):215-7. PubMed ID: 23199543
[TBL] [Abstract][Full Text] [Related]
8. Renin angiotensin system (RAS) blockade and diabetic microvascular complications in the eye and kidney.
Bilous R
Prim Care Diabetes; 2008 Dec; 2(4):201-2. PubMed ID: 18760685
[No Abstract] [Full Text] [Related]
9. [Type 2 diabetes and nephropathy--new studies, new treatment strategies?].
Os I; Stenehjem A; Høieggen A; Draganov B; Jenssen T; Holdaas H
Tidsskr Nor Laegeforen; 2002 Apr; 122(9):918-20. PubMed ID: 12082835
[TBL] [Abstract][Full Text] [Related]
10. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
Vogt L; Kocks MJ; Laverman GD; Navis G
Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
[TBL] [Abstract][Full Text] [Related]
11. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
Jacobsen P; Rossing K; Parving HH
Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
[TBL] [Abstract][Full Text] [Related]
12. [The angiotensin II inhibition escape phenomenon in patients with type 2 diabetes and diabetic nephropathy].
Shamkhlova MSh; Trubitsyna NP; Katsaia GV; Goncharov NP; Malysheva NM; Il'in AV; Nikankina LV; Koshel' LV; Shestakova MV
Ter Arkh; 2008; 80(1):49-52. PubMed ID: 18326228
[TBL] [Abstract][Full Text] [Related]
13. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH
Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
[TBL] [Abstract][Full Text] [Related]
14. [Dual blockade of the renin-angiotensin system].
Andersen NH; Mogensen CE
Ugeskr Laeger; 2004 Oct; 166(43):3799-803. PubMed ID: 15544108
[No Abstract] [Full Text] [Related]
15. Comparative effect of lisinopril and lacidipine on urinary albumin excretion in patients with type 11 diabetic nephropathy.
Salako BL; Finomo FO; Kadiri S; Arije A; Olatosin AO
Afr J Med Med Sci; 2002 Mar; 31(1):53-7. PubMed ID: 12518931
[TBL] [Abstract][Full Text] [Related]
16. Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease.
Feng YH; Fu P
Chin Med J (Engl); 2016 Jan; 129(1):81-7. PubMed ID: 26712437
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
Hughes DB; Britton ML
Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
[TBL] [Abstract][Full Text] [Related]
18. [Hypertension in patients with diabetes].
Poulsen PL; Hansen KW; Gaede PH; Rossing P
Ugeskr Laeger; 2009 Jun; 171(24):2031-4. PubMed ID: 19523370
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study.
Morikawa A; Ishizeki K; Iwashima Y; Yokoyama H; Muto E; Oshima E; Sekiguchi M; Miura T; Itoh H; Haneda M
Clin Exp Nephrol; 2011 Dec; 15(6):848-53. PubMed ID: 21823043
[TBL] [Abstract][Full Text] [Related]
20. Ongoing treatment with renin-angiotensin-aldosterone-blocking agents does not predict normoalbuminuric renal impairment in a general type 2 diabetes population.
Afghahi H; Miftaraj M; Svensson AM; Hadimeri H; Gudbjörnsdottir S; Eliasson B; Svensson MK;
J Diabetes Complications; 2013; 27(3):229-34. PubMed ID: 23246248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
